Evidence map›Paper›PMID 41044136›Full record

ArticleScientific reports2025

Characterization of the mutational status of glioblastoma and high-grade astrocytomas in a Latin American cohort.

Rodrigo Fernández-Gajardo, Hery Urra, Mauricio Sáez, Philippe Pihán, Beatriz Fonseca, Carolina Sanchez-Doñas, Gabriel Cavada, Claudia Tissera, Rómulo Melo, David Rojas-Zalazar and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rodrigo Fernández-GajardoProgram of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, 1027 Independencia Av., Santiago, Chile.
Hery UrraFONDAP Center for Geroscience, Brain Health, and Metabolism (GERO), Santiago, Chile.
Mauricio SáezDepartment of Diagnostic and Evaluation Processes, Faculty of Health Sciences, Universidad Católica de Temuco, Temuco, Chile.
Philippe PihánProgram of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, 1027 Independencia Av., Santiago, Chile.
Beatriz FonsecaAdvanced Genomics Core, Universidad Mayor, Santiago, Chile.
Carolina Sanchez-DoñasAdvanced Genomics Core, Universidad Mayor, Santiago, Chile.
Gabriel CavadaPublic Health Department, Faculty of medicine, University of Chile, Santiago, Chile.
Claudia TisseraPathology Department, Asenjo Neurosurgery Institute, Santiago, Chile.
Rómulo MeloDepartment of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
David Rojas-ZalazarDepartment of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
José M MatamalaBiomedical Neuroscience Institute (BNI), Faculty of Medicine, University of Chile, Santiago, Chile. jm_matamala@med.uchile.cl.
Claudio HetzProgram of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, 1027 Independencia Av., Santiago, Chile. chetz@uchile.cl.

Funding

Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias 15150012Fondo de Fomento al Desarrollo Científico y Tecnológico ID1ID22I10120Fondo Nacional de Desarrollo Científico y Tecnológico 11180825Fondo Nacional de Desarrollo Científico y Tecnológico 1220573Fondo Nacional de Desarrollo Científico y Tecnológico 3210294Millennium Institute P09-015-FSwiss Consolidation Grant The Leading House for the Latin American RegionU.S. Air Force Office of Scientific Research FA9550-21-1-0096U.S. Department of Defense W81XWH2110960
6 · The paper itself

Abstract

High-grade astrocytomas vary in incidence and mortality across populations, with Hispanic and Latino groups largely underrepresented in genomic epidemiology studies. This study characterizes the presence of known mutations of high-grade astrocytomas in a Latin American cohort through targeted genomic analysis of 70 Chilean patients. Molecular markers, including IDH, TERTp, H3, TP53, PTEN, EGFR, and CDKN2A, were assessed alongside survival analyses. Our results mostly aligned with international cohorts, confirming the importance of established molecular markers in glioblastoma. Novel damaging TP53 and PTEN mutations were identified, expanding the genetic spectrum of known mutations for these genes, while a lower-than-expected NF1 mutation frequency was observed (p < 0.01). These findings highlight the importance of examining underrepresented populations, providing insights into the molecular characteristics of high-grade astrocytomas in Latin America. Our findings contribute to understanding the diversity of genomic features across astrocytoma populations, setting a foundation for future international comparative studies.

Indexed as

AstrocytomaBrain NeoplasmsGlioblastomaMutationAdultAgedBiomarkers, TumorChileCohort StudiesFemaleHumansLatin AmericaMaleMiddle AgedNeoplasm GradingPTEN PhosphohydrolaseBiomarkers, TumorPTEN PhosphohydrolasePTEN protein, humanTP53 protein, humanTumor Suppressor Protein p53Genomic epidemiologyGlioblastomaNext-generation sequencingPrecision medicineUnderrepresented populations

Identifiers

PMID41044136
PMCPMC12494855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.